KRAS and cancer: Upon binding to the mutant, RMC-9805 forms a stable complex with KRAS G12D and cyclophilin A, leading to suppression of RAS pathway activity, inhibition of cancer cell proliferation, and apoptosis induction in vitro and in most preclinical PDAC and NSCLC cancer models when used alone [92].